. 2020 Jun 12;20:410. doi: 10.1186/s12879-020-05126-z

Table 3.

Comparisons of CrAg positivity, incidence of CM and all-cause mortality among HIV-infected persons stratified by CD4+ T cell count

Author, year	Prevalence of CrAg positivity		Incidence of CM				All-cause mortality
	CD4<100 (cells/μL)	CD4 100 ~ 200 (cells/μL)	CD4<100 (cells/μL)		CD4 100 ~ 200 (cells/μL)		CD4<100 (cells/μL)		CD4 100 ~ 200 (cells/μL)
			with antifungal treatment	without antifungal treatment	with antifungal treatment	without antifungal treatment	with antifungal treatment	without antifungal treatment	with antifungal treatment	without antifungal treatment
Chariyalertsak, 2002 [25]	Not reported		0 of 40	6 of 45	0 of 23	0 of 21	Not reported		Not reported
Parkes-Ratanshi, 2011 [18]	Not reported		17 of 698		2 of 821		3^a of 698		0^a of 821
McKinsey, 1999 [19]	Not reported		0 of 101	7 of 103	1 of 48	1 of 43	Not reported		Not reported
Meya, 2010 [21]	26 of 295	7 of 298	3 of 21	2 of 5	Not reported		6 of 21	5 of 5	0 of 4	1 of 3
Govender, 2015 [1]	20 of 708	6 of 371	Not reported		Not reported		Not reported		Not reported
Borges, 2019 [24]	12 of 159	5 of 5	0 of 9	0 of 3	0 of 1	1 of 4	Not reported		Not reported
	Pooled CrAg + prevalence: 0.06 [−0.02, 0.11], p = 0.001, I² = 86.5%	Pooled CrAg + prevalence: 0.02 [0.01, 0.03], p = 0.146, I² = 48%	Risk ratio with 95%CI: 7.67 [2.03, 29.05], p = 0.36, I² = 1%		Risk ratio with 95%CI: 1.15 [0.16, 8.13], p = 0.97, I² = 0%		Risk ratio with 95%CI: 0.32 [0.16, 0.64], p and I² not applicable		Risk ratio with 95%CI: 0.27 [0.01, 4.93], p and I² not applicable
Risk ratio with 95%CI	1.82 [0.77, 4.30], p = 0.007, I² = 63%		2.53 [0.50, 12.71], p = 0.26, I² = 59%				4.15 [0.89, 19.42], p = 0.07, I² = 0%

^a Died within 4 weeks